Dallas, Texas 04/29/2014 (FINANCIALSTRENDS) – Array BiopharmaInc (NASDAQ:ARRY) the biopharmaceutical with a variety of cancer and inflammation causing diseases has reported that it will announce its quarterly results on April 29, 2014.
Array BiopharmaInc (NASDAQ:ARRY)has reported its previous quarter earnings in early Feb. As per those result declarations, the stock had announced that its earnings were to the tune of $0.13 per share and that it beat consensus estimate by $0.16 by $0.03. The revenue for this quarter, according to the company is $14.10 million and has proved to be a consensus estimate which borders on $13.49 million. However, in the previous quarter, of 2013, the comparative earnings were to the tune of 23.4%.
Separately, leading analysts such as Zacks have announced that it will offer a downgrade on the stock. The outperform rating for the stock is currently ‘neutral.’ However, in the near future, the shares will now hold a $4.50 price target on the stock.
Array BiopharmaInc (NASDAQ:ARRY) has been one of the lead pharmaceuticals which have discovered as well as developed small molecule drugs for commercial purposes. The biopharmaceutical will also look at treating patients who are afflicted and are down with cancer and a range of inflammatory health conditions.
Array BiopharmaInc (NASDAQ:ARRY) will continue to see pipeline development for clinical candidates. The design of the product is to ensure therapy products as well as target pathways for important services.
Array Biopharma has several drug candidates which includes development as well as commercialization purposes. The stock has a 52 week trading price of $3.39 low and $7.10 high. Marketing capital for this stock is in the region of 484.26 million. EPS for this stock is -0.60. Outstanding shares for this stock are in the region of 125.46 million. Beta for this stock is 1.86.